Abstract:Introduction The ongoing donor kidney shortage has necessitated the increasing use of higher Kidney Donor Profile Index (KDPI) kidneys. Our aim was to investigate machine perfusion (MP) as a strategy to optimise outcomes from these grafts, in particular through the pharmacologic targeting of ischaemia-reperfusion injury (IRI). Materials/Methods (i) A systematic review/meta-analysis was conducted to compare renal transplantation outcomes after hypothermic (HMP) and normothermic (NMP) MP in comparison to static cold storage (CS) using both clinical and experimental data, and thence identify areas for further investigation using animal experimental models. (ii) Directed drug delivery to the kidney, delivered using MP and targeting IRI, was identified as an important area for further research. Three different IRI targets (CD47 antibody, soluble complement receptor 1 [sCR1], and recombinant thrombomodulin [rTM]), delivered intra-renally, were therefore compared in a rodent model of kidney IRI. (iii) NMP was identified as a promising preservation modality for further clinical implementation; therefore a NMP system was developed/optimised using a porcine donation after cirulatory death (DCD) model. The impact of CD47 and sCR1 on NMP parameters was subsequently investigated. Results (i) Hypothermic MP (HMP) reduces kidney delayed graft function in comparison to CS (RR 0.77, 95% CI 0.69 to 0.87), but there is no cumulative study evidence for an improvement in longer-term outcomes. NMP evidence is largely limited to the experimental setting and indicates that NMP is superior to HMP with regards to subsequent renal function (mean difference of peak creatinine -1.66; 95% CI -3.19 to -0.14). Drug delivery targeting IRI is under-explored in MP studies. (ii) A rodent renal IRI model was established, and preliminary evidence (day 1 and 7 renal function and histopathology) indicates intra-renal delivery of CD47 and/or soluble complement receptor 1 may ameliorate IRI. (iii) A clinically translatable NMP system was developed and tested using a porcine kidney donation after circulatory death model. Pressure-controlled perfusion, using a leukocyte-depleted, colloid-containing perfusate produced ideal baseline conditions. Addition of CD47 to the perfusion circuit impacts on perfusion and biochemical parameters, including intra-renal resistance, urine output, and creatinine clearance. Discussion Renal HMP does not seem to modulate longer-term graft outcomes. IRI of the kidney can be ameliorated by the intra-renal delivery of pharmocotherapies such as CD47 blocking antibody. NMP presents the ideal opportunity to deliver such IRI-targeting drugs to the kidney and simultaneously assess kidney function and may enhance the impact of this preservation modality. Conclusion Modification of perfusion conditions using NMP in combination with drug(s) targeting IRI may further improve transplantation outcomes, and avoids systemic treatment of the donor or recipient.

Targeting of intragraft reactive oxygen species by APP‐103, a novel polymer product, mitigates ischemia/reperfusion injury and promotes the survival of renal transplants

Ex Vivo Anchored PD‐L1 Functionally Prevent in Vivo Renal Allograft Rejection

Role of Reactive Oxygen Species in Mediating Hepatic Ischemia-Reperfusion Injury and Its Therapeutic Applications in Liver Transplantation

Antioxidant Polysulfide Nanoparticles Ameliorate Ischemia-Reperfusion Injury and Improve Porcine Kidney Function Post-Transplantation

High-pressure carbon monoxide preserves rat kidney grafts from apoptosis and inflammation

CD4+CD25+FOXP3+ regulatory T cells: a potential "armor" to shield "transplanted allografts" in the war against ischemia reperfusion injury

New therapeutic concepts against ischemia-reperfusion injury in organ transplantation

In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection

Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia

Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform

Melanin-like nanoparticles alleviate ischemia-reperfusion injury in the kidney by scavenging reactive oxygen species and inhibiting ferroptosis

Activation of the PPARγ/NF-κB pathway by A-MPDA@Fe3O4@PVP via scavenging reactive oxygen species to alleviate hepatic ischemia-reperfusion injury

Resveratrol Alleviates Inflammatory Responses and Oxidative Stress in Rat Kidney Ischemia-Reperfusion Injury and H2O2-Induced NRK-52E Cells via the Nrf2/TLR4/NF-κB Pathway

Lack of Long-Term Protective Effect of Antioxidant/Anti-Inflammatory Therapy in Transplant-Induced Ischemia/Reperfusion Injury

Intracellular Reactive Oxygen Species Mediate the Therapeutic Effect of Induced Pluripotent Stem Cells for Acute Kidney Injury

Targeting peripheral immune organs with self‐assembling prodrug nanoparticles ameliorates allogeneic heart transplant rejection

An enzyme-mimicking reactive oxygen species scavenger targeting oxidative stress-inflammation cycle ameliorates IR-AKI by inhibiting pyruvate dehydrogenase kinase 4

Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation

Reactive Oxygen Species Responsive Multifunctional Fusion Extracellular Nanovesicles: Prospective Treatments for Acute Heart Transplant Rejection

Intra-Renal Delivery of Drugs Targeting Ischemia-Reperfusion Injury of the Kidney using Normothermic Machine Perfusion

PPAR-γ activation promotes xenogenic bioroot regeneration by attenuating the xenograft induced-oxidative stress